protein

LILRB4/CD85k/ILT3 Protein, Human (Biotinylated, HEK293, His-Avi)

HY-P77744

20 μg;50 μg

195;428 USD

LILRB4/CD85k/ILT3 Protein, Human (Biotinylated, HEK293, His-Avi)

proteins

HEK293

20 μg;50 μg

195;428 USD

The LILRB4/CD85k/ILT3 protein is a key inhibitory receptor that plays a key role in immune regulation and tolerance. As a receptor for FN1, apolipoprotein APOE, and ALCAM/CD166, it inhibits receptor-mediated phosphorylation, intracellular calcium mobilization, and FCGR1A/CD64-mediated monocyte activation, thereby reducing TNF production. LILRB4/CD85k/ILT3 Protein, Human (Biotinylated, HEK293, His-Avi) is the recombinant human-derived LILRB4/CD85k/ILT3 protein, expressed by HEK293 , with C-Avi, C-His labeled tag.

Human

LILRB4/CD85k/ILT3, an inhibitory receptor, plays a pivotal role in immune regulation and the establishment of immune tolerance. Functioning as a receptor for FN1, apolipoprotein APOE, and ALCAM/CD166, this protein is involved in diverse cellular processes. It inhibits receptor-mediated phosphorylation of cellular proteins and the mobilization of intracellular calcium ions, and it further down-regulates FCGR1A/CD64-mediated monocyte activation, leading to reduced TNF production. Additionally, LILRB4/ILT3 impedes T cell proliferation, inducing anergy, suppressing the differentiation of IFNG-producing CD8+ cytotoxic T cells, and promoting the generation of CD8+ T suppressor cells. It induces the up-regulation of CD86 on dendritic cells and interferes with TNFRSF5-signaling and NF-kappa-B up-regulation. The inhibitory effects are at least partially mediated through interactions with FN1 and the phosphatase PTPN6.

HM18; ILT3; ILT-3; LILRB4; LIR5; CD85K

Greater than 95% as determined by Tris-Bis PAGE.

Lyophilized from a 0.22 μm filtered solution of PBS, pH 7.4. Normally 5% trehalose is added as protectant before lyophilization.

Room temperature in continental US; may vary elsewhere.